IDWeek 2026: Abrysvo data in nursing home residents could support re-vaccination
Abrysvo was first approved in the US in 2023 for the prevention of lower respiratory tract disease (LRTD) caused by RSV.
Abrysvo was first approved in the US in 2023 for the prevention of lower respiratory tract disease (LRTD) caused by RSV.